Puma Biotechnology, Inc., a development-stage biopharmaceutical company based in Los Angeles, United States, continues to focus on its mission to develop novel therapeutics for the treatment of various forms of cancer. Operating within the Health Care sector and the Biotechnology industry, Puma Biotechnology specializes in in-licensing drug candidates that have already undergone and completed initial clinical testing. The company aims to further develop these candidates into effective cancer treatments, leveraging its expertise in biopharmaceutical development.
As of 23 February 2026, Puma Biotechnology’s stock closed at $7.49 on the Nasdaq, nearing its 52-week high of $7.58, which was recorded just two days prior. This performance reflects a significant recovery from its 52-week low of $2.58, observed on 8 April 2025. The stock’s volatility range of $5.00 highlights the dynamic nature of its market performance over the past year.
Financially, Puma Biotechnology is valued at a market capitalization of $358.28 million. The company’s valuation metrics include a price-to-earnings ratio of 9.55 and a price-to-book ratio of 2.99. These figures suggest a moderate valuation relative to both its earnings and book value, indicating a balanced market perception of its financial health and growth potential.
In terms of corporate activities, Puma Biotechnology remains in a quiet reporting phase, with its most recent public disclosure dated 24 February 2026 from Biospace. Despite this, the company is actively engaging with investors and industry peers, as evidenced by its scheduled appearance at TD Cowen’s 46th Annual Health Care Conference. This participation underscores Puma Biotechnology’s commitment to maintaining open lines of communication with stakeholders and staying abreast of industry developments.
For more detailed information about Puma Biotechnology’s initiatives and ongoing projects, interested parties are encouraged to visit their official website at www.pumabiotechnology.com .
